A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis

PHASE2CompletedINTERVENTIONAL
Enrollment

280

Participants

Timeline

Start Date

January 30, 2018

Primary Completion Date

February 7, 2019

Study Completion Date

May 23, 2019

Conditions
Atopic Dermatitis
Interventions
BIOLOGICAL

Lebrikizumab

Sterile liquid solution administered subcutaneously.

DRUG

Placebo

Solution administered subcutaneously.

Trial Locations (58)

10022

Schweiger Dermatology, PLLC, New York

10029

Icahn School of Medicine, New York

10075

Sadick Research Group, LLC., New York

11790

DermResearchCenter of New York, Inc., Stony Brook

20037

George Washington Medical Faculty Associates, Washington D.C.

20850

Dermatology and Skin Cancer Specialists, LLC, Rockville

23502

Virginia Clinical Research, Inc., Norfolk

27612

Wake Research Associates, LLC, Raleigh

28277

Piedmont Plastic Surgery and Dermatology, Charlotte

28405

Wilmington Dermatology Center, Wilmington

29407

Clinical Research Center of the Carolinas, Charleston

30060

Marietta Dermatology Clinical Research, Inc., Marietta

30328

Advanced Medical Research, PC, Sandy Springs

32771

International Clinical Research - US, LLC, Sanford

33134

Florida Academic Centers Research and Education, LLC, Coral Gables

33162

Tory Sullivan, MD PA, North Miami Beach

33406

Integrated Clinical Research, LLC, West Palm Beach

33437

Total Vein and Skin, Boynton Beach

33770

Olympian Clinical Research, Largo

37072

Rivergate Dermatology Clinical Research Center, Goodlettsville

37130

International Clinical Research - Tennessee LLC, Murfreesboro

37215

Tennessee Clinical Research Center, Nashville

40217

Skin Sciences, PLLC, Louisville

44106

University Hospitals Cleveland Medical Center, Cleveland

46168

The Indiana Clinical Trials Center, Plainfield

46256

Dawes Fretzin Clinical Research Group, LLC, Indianapolis

48084

Somerset Skin Centre, Troy

60118

Dundee Dermatology, West Dundee

66215

Kansas City Dermatology, PA, Overland Park

70808

Meridian Clinical Research, LLC, Baton Rouge

72022

Dermatology Trial Associates, Bryant

72758

Northwest Arkansas Clinical Trials Center, Rogers

73112

Lynn Health Science Institute, Oklahoma City

75246

Menter Dermatology Research, Dallas

76011

Arlington Research Center, Inc., Arlington

77030

The University of Texas Health, Houston

77401

Bellaire Dermatology Associates, Bellaire

77598

Center for Clinical Studies, LTD. LLP, Webster

78213

Progressive Clinical Research, PA, San Antonio

78746

Westlake Dermatology Clinical Research Center, Austin

85255

Clear Dermatology & Aesthetics Center, Scottsdale

87106

Academic Dermatology Associates, Albuquerque

89148

JDR Dermatology Research, Las Vegas

90033

University of Southern California, Los Angeles

90045

Dermatology Research Associates, Los Angeles

90404

Clinical Science Institute, Santa Monica

92122

UCSD Dermatology, San Diego

92123

TCR Medical Corporation, San Diego

94063

Stanford Medicine Outpatient Center-Medical Dermatology Clinic, Redwood City

94538

Center for Dermatology Clinical Research, Inc., Fremont

95819

Center for Dermatology and Laser Surgery, Sacramento

97223

Oregon Medical Research Center, Portland

98101

Dermatology Associates of Seattle, Seattle

99202

Premier Clinical Research, Spokane

01915

ActivMed Practices & Research, Inc., Beverly

02111

Tufts Medical Center, Boston

03801

ActivMed Practices & Research, Inc., Portsmouth

02919

Clinical Partners, LLC, Johnston

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Dermira, Inc.

INDUSTRY

lead

Eli Lilly and Company

INDUSTRY

NCT03443024 - A Study of Lebrikizumab (LY3650150) in Participants With Moderate-to-Severe Atopic Dermatitis | Biotech Hunter | Biotech Hunter